Author

Phillip Levine

Observed institution: AbbVie (United States)

OpenAlex ID: A5067362286

Risankizumab for Ulcerative Colitis

2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134

Reflux Events Detected by pH‐MII Do Not Determine Fundoplication Outcome

2010 · Rachel Rosen, Phillip Levine, et al. · Journal of Pediatric Gastroenterology and Nutrition · 54

S845 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

2023 · Edouard Louis, Remo Panaccione, et al. · The American Journal of Gastroenterology · 8

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

2026 · Walter Reinisch, David Stepek, et al. · The Lancet. Gastroenterology & hepatology · 7

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

2026 · Vipul Jairath, Jaroslaw Kierkuś, et al. · The Lancet. Gastroenterology & hepatology · 7

S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

2023 · Edouard Louis, Remo Panaccione, et al. · The American Journal of Gastroenterology · 3

904 Additional Risankizumab Therapy Is Effective in Patients With Moderately to Severely Active Ulcerative Colitis Who Did Not Achieve Clinical Response to Initial 12-week Induction Therapy: an Analysis of Phase 3 Inspire and Command Studies

2024 · Remo Panaccione, Gil Melmed, et al. · Gastroenterology · 2

984 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 Command Study

2024 · Stefan Schreiber, Remo Panaccione, et al. · Gastroenterology · 2

911a: DUVAKITUG INDUCTION TREATMENT IMPROVES ENDOSCOPIC AND PATIENT-REPORTED CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE: AN ENDOSCOPIC SUBGROUP ANALYSIS OF DATA FROM THE RELIEVE-UCCD PHASE 2B STUDY

2025 · Vipul Jairath, Bruce E. Sands, et al. · Gastroenterology · 1

987d: DUVAKITUG INDUCTION TREATMENT IMPROVES CLINICAL AND ENDOSCOPIC OUTCOMES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN ENDOSCOPIC SUBGROUP ANALYSIS OF DATA FROM THE RELIEVE-UCCD PHASE 2B STUDY

2025 · Walter Reinisch, Silvio Danese, et al. · Gastroenterology · 1

P22 Economic impact of risankizumab induction therapy on UC-related hospitalisations and work productivity: data from the phase 3 induction study

2025 · Parambir S Dulai, Raymond K Cross, et al.

Tu1102 ECONOMIC IMPACT OF RISANKIZUMAB INDUCTION THERAPY ON UCRELATED HOSPITALIZATIONS AND WORK PRODUCTIVITY: AN ANALYSIS OF DATA FROM THE PHASE 3 INSPIRE TRIAL

2024 · Parambir S. Dulai, Raymond K. Cross, et al. · Gastroenterology

Su1792 EFFICACY OUTCOMES OF PLACEBO MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RESPONDED TO PLACEBO INDUCTION THERAPY: RESULTS FROM THE PHASE 3 COMMAND STUDY

2024 · Raja Atreya, Marc Ferrante, et al. · Gastroenterology

M1099 Symptom Association During Impedance Testing (pH-MII) Is Not Useful in Predicting Outcome After Fundoplication

2008 · Rachel Rosen, Phillip Levine, et al. · Gastroenterology

Works count: 14

Citation count: 217

H-index: 5

I10-index: 2